FDA Investigator Brooke K Seeman

Brooke K Seeman has conducted inspections on 27 sites in 2 countries as of 14 Apr 2008. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
27
Last Inspection Date:
14 Apr 2008
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
United States of America, Italy
FDA Investigators that have inspected at least one site in common with Brooke K Seeman:
Alicia M Mozzachio, Alison N Stieg, Amy N Chen, Anastasia I Onuorah, Anastasia M Shields, Andrew O Ejiofor, Annet R Rajan, Anthony F Lorenzo, Anthony W Lee, Atul J Agrawal, Benjamin J Smith, Bo Chi, PhD, Brian R Yaun, Brooke K Higgins, Burnell M Henry, Candice C Mandera, Candice J Cortes, Carol L Rehkopf, Carole L Jones, Caroline Strasinger, CDR Ileana Barreto Pettit, Chaltu Nwakijra, Christian D Lynch (CDL), Chryste D Best, Clarice J Ahn, Cody D Rickman, Colleen F Hoyt, Colleen Thomas, PhD, David A Oluwo, Dennis Cantellops Paite, Dennis L Doupnik, Derek S Smith, PhD, Diane T Bargo, Diane T O'brien, Dianne H Milazzo, Donald L Lech, Douglas A Campbell, Dr. Gang Wang, PhD, Edmund F Mrak, Jr, Edwin Melendez, Emest F Bizjak, Emmanuel A Dimaano, Jr, Ephrem Hunde, PhD, Eric L Dong, BS, Frederick F Razzaghi, Gayle S Lawson, Geneve M Maxwell, Geneve M Parks, George Pyramides, Gerald B Seaborn, Jr, Gerald D Bromley, Jr, Gifford Whitehurst, Jr, Guerlain Ulysse, Hongna Wang, Howard Anderson, PhD, Jacqueline Mdiaz Albertini, Jacqueline S Warner, James C Maclaughlin, James M Mason, James M Simpson, James W Leonette, Janet A Rajan, Jazmine N Still, Jean Blackston Hill, Jeffrey A Sommers, Jeffrey D Meng, Jessica Hankins, PhD, Jessica L Pressley, Jingbo Xiao, Joey C West, Jogy George, John P Mistler, Johnna L Bleem, Jonah S Ufferfilge, Jonathan W Chapman, Jose R Hernandez, Junho Pak, Justin A Boyd, Karen A Briggs, Katelyn Astaub Zamperini, Kathleen M Jordan, Kelly L Anderson, Kenneth M Gordon, Kenneth Nieves, Ko U Min, Kristina L Conroy, Kshitij A Patkar, Lakshmi Narasimhan, PhD, Larry K Austin, Laurissa S Flowers, Lawrence Harmon, Jr, Lawrence J Stringer, LCDR Anastasia M Piliafas Brown, LCDR Debra Emerson, Lisa L Flores, Lori A Holmquist, Lori S Lawless, Luella J Rossi, Luis A Dasta, Lynette P Salisbury, Malgorzata G Norton, PhD, Marcellinus D Dordunoo, Marcus A Ray, Maria Gutierrez Lugo, PhD, Marie F Morin, Marion Michaelis, Massoud Motamed, Matthew M Henciak, Meisha R Sampson, Meisha Waters, Melissa J Garcia, Melissa T Roy, Merideth K Rose, Michael G Truchan, Michael J Vardon, Michele L Forster, PhD, Michelle Marsh, Mihaly S Ligmond, Muna Algharibeh, Nancy M Espinal, Nathaniel R Esaw, Nawab A Siddiqui, Nebil A Oumer, Nerizza B Guerin, Nicholas A Violand, Nicole K Trudel, Parul M Patel, Patricia A Morrow, Patrick C Klotzbuecher, Paula J Bretz, Prabhu P Raju, Pratik S Upadhyay, DDC, Qin Xu, Quyen T Tran, Rabin N Ghoshal, Rachel C Harrington, Reba A Gates, Rebecca E Dombrowski, Rebecca Rodriguez, Regina Gibson Melton, Robert J Maffei, Robert J Martin, Robert M Barbosa, Robin Levis, PhD, Roy R Rinc, Ruark Lanham, Saleem A Akhtar, Sean R Marcsisin, Sena G Dissmeyer, Sharon K Thoma, PharmD, Shirshendu K Deb, PhD, Shusheen A Alexander, Sneha S Patel, Stephen C Eason, Steven E Bowen, PhD, Steven J Thurber, Steven P Donald, Susan M Jackson, Suzanne M Healy, Suzanne M Muchene, Swati Verma, Tajah L Blackburn, Tamika White, Tamil Arasu, PhD, Temar Q Williams, Thai D Truong, Thomas J Arista, Thomas R Withers, Tiffani D Wilson, Toyin B Oladimeji, Vesna V Stanoyevitch, Vipulchandra N Dholakia, Walter L Fava, Wanda Y Fields, Wanda Y Honeyblue, William A Warnick, William H Linkroum, William J Leonard, William L Bargo, Yvonne C Mcknight, Zhenzhen Liu, PhD

Brooke K Seeman's Documents

Publish Date Document Type Title
June, 2004 FDA 483 Atley Pharmaceuticals, Inc. - Form 483, 2004-06-24
June, 2005 FDA 483 Response Total Homecare Inc. - Form 483R, 2005-06-10
December, 2004 FDA 483 Patient First Corporation - Form 483, 2004-12-09
October, 2007 FDA 483 Afton Scientific, LLC - Form 483, 2007-10-23
June, 2005 FDA 483 Total Homecare Inc. - Form 483, 2005-06-06
March, 2006 FDA 483 Cangene BioPharma, LLC - Form 483, 2006-03-31
August, 2005 FDA 483 Response Exelead, Inc. - Form 483R, 2005-09-15
August, 2005 EIR Exelead, Inc. - EIR, 2005-08-19
March, 2008 FDA 483 Fareva Richmond, Inc. - Form 483, 2008-03-13
June, 2007 EIR Actavis Mid-Atlantic, LLC. - EIR, 2007-06-22
June, 2003 EIR Mylan Pharmaceuticals Inc. - EIR, 2003-06-17
January, 2004 EIR Reckitt Benckiser Pharmaceuticals Inc - EIR, 2004-01-23
March, 2007 FDA 483 Neilgen Pharmaceutical Inc Dba Unigen Pharmaceuticals - Form 483, 2007-03-22
July, 2003 EIR Fareva Richmond, Inc. - EIR, 2003-07-18
September, 2004 EIR Boehringer Ingelheim Chemicals, Inc. - EIR, 2004-09-13
April, 2008 FDA 483 Bell-More Labs Inc - Form 483, 2008-04-23
June, 2005 EIR Total Homecare Inc. - EIR, 2005-06-06
February, 2008 FDA 483 Neilgen Pharmaceutical Inc Dba Unigen Pharmaceuticals - Form 483, 2008-02-15
September, 2006 FDA 483 Boehringer Ingelheim Chemicals, Inc. - Form 483, 2006-09-15
June, 2004 FDA 483 DanChem Technologies Inc - Form 483, 2004-06-23
September, 2006 FDA 483 Merck Sharp & Dohme LLC - Form 483, 2006-09-29
February, 2005 FDA 483 East Coast Oxygen & Hydro Testing Inc. - Form 483, 2005-02-18
August, 2005 FDA 483 Exelead, Inc. - Form 483, 2005-08-19
December, 2006 EIR F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. - EIR, 2006-12-13
March, 2004 FDA 483 Virginia Commonwealth University - Form 483, 2004-03-03
September, 2004 FDA 483 Boehringer Ingelheim Chemicals, Inc. - Form 483, 2004-09-13
October, 2004 FDA 483 Fareva Richmond, Inc. - Form 483, 2004-10-08
April, 2004 FDA 483 Barr Laboratories, Inc. (div. Of Teva) - Form 483, 2004-04-14
September, 2002 EIR Union Carbide Corporation, Subsidiary of Dow Chemical Compan - EIR, 2002-09-24
March, 2005 FDA 483 Fareva Richmond, Inc. - Form 483, 2005-03-31
August, 2006 FDA 483 Bell-More Labs Inc - Form 483, 2006-08-17
October, 2004 FDA 483 Biovail Technologies Ltd. - Form 483, 2004-10-29

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more